Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GBM cell lines capable of forming caveolae expressed more uPA and matrix metalloproteinase-2 (MMP-2) and/or -9 (MMP-9) and were more invasive than GBM cells devoid of caveola-forming proteins.
|
30949900 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analysed the transcript expression of CLEC5A in glioblastoma by accessing The Cancer Genome Atlas (TCGA). qRT-PCR was performed to detect the RNA expression of genes in cells and tissues, and Western blot was used to measure the protein levels (Cyclin D1, Bcl-2, BAX, PCNA, MMP2, MMP9, Akt and Akt phosphorylation) in tissues and cells.
|
30834619 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We showed a 20-fold upregulation of A<sub>2B</sub> AR on GB compared with sham, and its activation induced matrix metalloproteinase-2, which enhanced GB pathogenesis.
|
30926752 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus preclinical validation of molecular interaction between diosgenin and NFE2L2 down-regulating MMP-2, EMT markers and promoting apoptosis, offers rationale for new therapeutic horizons in the field of glioblastoma management.
|
30885764 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Zymography analysis also revealed that the activities of MMP-2 and MMP-9 of GBM cells were significantly inhibited in response to 100, 200, or 300 μM naringenin treatment.
|
30431227 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association of HSP27 with MMP-2 and MMP-9 proteins along with the identified interacting stretch has the potential to contribute towards drug development to inhibit GBM infiltration and migration.
|
31028823 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of the miR-221/222 cluster diminished the invasion, migration, proliferation, and angiogenesis with reduced protein levels of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor in glioblastoma cells.
|
31106423 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DTCM-g also reduces the invasion capacity of all GBM cell lines without alterations in MMP2 and uPa expression.
|
29683097 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor growth rate and final tumor weight were significantly increased in the animals with the glioblastoma derived from transfected U87-H4645 cells, compared to untransfected and vector control (p<0.01). mRNA expression of β-catenin, CD44, ICAM-1, and MMP-2 in the glioblastoma derived from the transfected U87-H4645 tumors was significantly increased compared with tumors derived from untransfected and vector-control U87 cells (p<0.01).
|
29848673 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/AKT signaling prevented the suppressive effects of RWDD3 downregulation on glioblastoma cell proliferation and migration, concurrent with increased protein levels of MMP2 and MMP9.
|
29977365 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma.
|
28600709 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Human glioblastomas express higher levels of matrix metalloprotease-2 (MMP-2) than low-grade brain tumors and normal brain tissues.
|
28569433 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blotting was used to determine the protein levels of TSHZ3 and MMP2 in glioblastoma cell lines and Matrigel invasion assay to examine the role of miR-338-5p in cell invasiveness.
|
28780604 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tivozanib diminished GBM cell invasion through impairing the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).
|
28287096 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Measurements of MMP-2 intensity increased with tumor grade, and MMP-2 expression was found to be significantly higher in glioblastomas compared to normal brain tissue (p<0.001), diffuse astrocytomas (p<0.001) and anaplastic astrocytomas (p<0.05).
|
28234925 |
2017 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma T-98G cells expressed only one band corresponding to MMP-2.
|
28112361 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment could target the Matrix metalloproteinase-2 (MMP-2), which is known to be involved in the invasion process of glioblastoma cells.
|
27678152 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, our data suggest that MMP2 and E-cadherin, a key factor in epithelial-mesenchymal transition (EMT), are involved in the miR-633/TGF-β1-mediated metastasis of glioblastoma.
|
26717894 |
2016 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.
|
25948484 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that VEGFa may regulate MMP2 in glioblastoma, while MMP2 did not appear to affect VEGFa levels.
|
25213694 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant decline of MMP-9 and MMP-2 secretion in cultured U87MG was detected after incubation with EBB (42.9% and 73.0%, respectively) and EBB + TMZ (38.4% and 68.5%, respectively).
|
25256634 |
2014 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We find that MMP-2 activity in human U251 GBM xenografts increases (*P=0.03) and collagen IV content decreases (*P=0.01) during vascular endothelial growth factor (VEGF-A) antibody neutralization.
|
22673390 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The data presented here suggest that miR-223 promotes the growth and invasion of U251 and U373 glioblastoma cells by targeting PAX6, which serves as a tumor suppressor in glioblastoma exerting the functions of inhibition of cell cycle transition, and the expression of MMP2, MMP9 and VEGFA.
|
23970099 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings demonstrated that hCGβ phosphorylated ERK1/2 upregulating MMP-2 expression and activity leading to cell migration and invasion, suggesting that hCGβ, ERK1/2 and MMP-2 are the potential targets to inhibit glioblastoma invasion.
|
23232806 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further research into the underlying mechanism demonstrated that the effects of miR-125b on the invasion of glioblastoma CD133-positive cells were associated with the alteration of the expression of MMPs (MMP-2 and MMP-9) and corresponding inhibitors (RECK and TIMP3).
|
22711523 |
2012 |